March 11, 2005 12:59 ET

New Reports and Studies Highlight Importance of Alzheimer's Disease Diagnosis




MARCH 11, 2005 - 12:59 ET

New Reports and Studies Highlight Importance of
Alzheimer's Disease Diagnosis

MAYWOOD, N.J.--(CCNMatthews - Mar 11, 2005) -

Nymox (NASDAQ:NYMX) Ad Test Now Available for Sale in Europe

A number of new studies and reports have highlighted the importance of
Alzheimer's disease diagnosis. A landmark new report by the World Health
Organization, Priority Medicines for Europe and the World, identified
the importance of early and accurate diagnosis of Alzheimer's disease.
The U.S. National Institute on Aging's most recent progress report, 2003
Progress Report on Alzheimer's Disease, highlighted the importance of an
early, accurate diagnosis to people with AD and their families. Other
studies include a newly released study (Neurology March 2005;
64:834-841) that found evidence that a significant percentage of the
elderly who showed signs of mental decline but were not diagnosed with
Alzheimer's disease were found on autopsy to have the pathologic
hallmarks of Alzheimer's disease in their brains.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) offers AlzheimAlert™,
a unique, non-invasive urine test intended to help physicians in the
diagnosis of Alzheimer's disease. The AlzheimAlert™ test detects
elevated levels of a brain protein called neural thread protein (NTP)
associated with Alzheimer's disease.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recently announced that a
kit version of its AlzheimAlert™ test is now available for sale to
clinical and hospital laboratories in the European Union. The
AlzheimAlert™ kit has been certified with the CE Mark, indicating
that the product complies with EU safety, environmental, quality and
regulatory standards. Since certification with the CE mark, the
AlzheimAlert™ kit has been registered for sale in 21 of the member
countries in the EU. Nymox recently announced the signing of a
distribution agreement for Italy with Alifax s.P.a.

AlzheimAlert™ testing is also available in the U.S. through the
Company's CLIA-certified clinical reference laboratory in Maywood, NJ at
a cost of $295.00 per test.

There is an extensive scientific and medical literature on NTP as a
biomarker for Alzheimer's disease and on its usefulness as an aid to the
diagnosis of Alzheimer's disease. Publications include, for example,
Journal of Alzheimer's Disease (2004; 6(3): 231-42) and (2001; 3:
345-353); Cellular and Molecular Life Sciences (2003; 60: 2679-91) and
(2001; 58: 844-849); Alzheimer's Reports (2002; 1: 1-6); Neurology &
Clinical Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002;
7:d989-96); Journal of Neuropathology and Experimental Neurology (2001;
60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and
(2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3:
177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis
(1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary
Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997;
100: 3093-3104).

According to a recent study (Arch Neurol 2003; 60: 1119-1122), there are
4.5 million people with Alzheimer's disease in the United States alone;
by 2050 this number is projected to increase almost three times to 13.2
million. Worldwide estimates of the current number of people with
Alzheimer's disease range from 15 to 20 million. The annual national
direct and indirect costs of caring for Alzheimer patients in the U.S.
alone are estimated at $100 billion. The human toll on patients,
families and caregivers is incalculable.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in
the research and development of therapeutics and diagnostics, with a
particular emphasis on products targeted for the unmet needs of the
aging population. Currently Nymox has three products on the market, and
a healthy pipeline of drug and diagnostic products. The Company also has
several hundred patents and patent applications. The Company has
successfully completed two U.S. Phase 1 and Phase 1-2 clinical trials
for NX-1207, its drug for benign prostatic hyperplasia (BPH). The
Company markets NicAlert™ and TobacAlert™ tests for measuring
tobacco product exposure. Nymox has a number of other drugs in
development for Alzheimer's disease, oncology, and infectious disease.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.


Contact Information

    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX